(Q34501951)

2 August 2017

1 reference

title

Use of chemo-radiotherapy in locally advanced non-small cell lung cancer (English)

1 reference

2 August 2017

Novello S

1

1 reference

2 August 2017

Le Chevalier T

series ordinal

2

1 reference

2 August 2017

publication date

1 January 2002

1 reference

European Journal of Cancer

2 August 2017

published in

1 reference

2 August 2017

volume

38

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

292-299

1 reference

2 August 2017

cites work

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the radiation therapy oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCL

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Signiicant Effect of Adjuvant Chemotherapy on Survival in Locally Advanced Non-Small-Cell Lung Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Turning up the heat on nonsmall cell lung cancer: is the toxicity of concurrent cisplatin-based chemotherapy and accelerated fractionation acceptable?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Mediastinal irradiation in lung cancer three years after heart transplantation: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Induction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900359-8

7 January 2021

10.1016/S0959-8049(01)00359-8

Identifiers

DOI

1 reference

2 August 2017

1 reference